Carsten Reinhardt
Management
Immatics Biotechnologies
Germany
Biography
Carsten Reinhardt joined Immatics Biotechnologies GmbH in October 2009 from Micromet, Inc. (Bethesda, MD), where he was Chief Medical Officer. Before becoming a member of Micromet´s management board in 2005, Dr Reinhardt had global responsibility for Herceptin® development as International Medical Leader at Hoffmann-La Roche (Basel, Switzerland). Prior to his tenure at Roche, Dr Reinhardt was Head of Clinical Development at Fresenius Biotech (Munich, Germany). Prior to joining industry, Dr Reinhardt held medical positions and worked at various academic institutions (University of Tuebingen, Max Planck Institute, Munich) to complete his curriculum in Neurology. Between 1991 and 1995, Dr Reinhardt completed his PhD thesis in Cellular Immunology at the Institute of Immunology in Munich, Germany (summa cum laude), and received a Medical Degree in 1994 from the University of Munich, Germany. Dr Reinhardt is a member of the American Society of Clinical Oncology, the American Society of Hematology, the Association for Cancer Immunotherapy as well as of the European Society of Medical Oncology, and is Visiting Professor for Pharmaceutical Medicine at the University of Basel. Dr Reinhardt has co-authored more than 30 publications in peer-reviewed journals including Science, Nature Medicine, Lancet, Journal of Clinical Oncology, Cancer Research, and Journal of Experimental Medicine.
Research Interest
Immunology
